Financial Performance - Outset Medical reported a quarterly loss of $0.84 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.76, and an improvement from a loss of $7.05 per share a year ago, representing an earnings surprise of +52.27% [1] - The company posted revenues of $31.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.54% and up from $27.39 million in the same quarter last year [2] Stock Performance - Outset Medical shares have declined approximately 15.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for Outset Medical is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$1.61 on revenues of $30.4 million, and for the current fiscal year, it is -$5.99 on revenues of $121.7 million [7] - The estimate revisions trend for Outset Medical was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical Info Systems industry, to which Outset Medical belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Inotiv, Inc. reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of +20.00% [1] - The company posted revenues of $130.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.94% and showing an increase from year-ago revenues of $105.79 million [2] - Over the last four quarters, Inotiv has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Inotiv shares have declined approximately 49.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.08 on revenues of $130.9 million, and for the current fiscal year, it is -$0.86 on revenues of $499.62 million [7] Industry Outlook - The Medical - Drugs industry, to which Inotiv belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Inotiv's stock performance [5]

Core Insights - CareDx reported quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share, and down from $0.25 per share a year ago, representing an earnings surprise of -16.67% [1] - The company posted revenues of $86.68 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.45%, and down from $92.27 million year-over-year [2] - CareDx shares have declined approximately 40% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $94.77 million, and for the current fiscal year, it is $0.60 on revenues of $371.5 million [7] - The estimate revisions trend for CareDx was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which CareDx belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Establishment Labs Holdings Inc., another company in the same industry, is expected to report a quarterly loss of $0.54 per share, with revenues anticipated to be $51.61 million, reflecting a 17% increase year-over-year [9][10]

Company Performance - PROCEPT BioRobotics Corporation reported a quarterly loss of $0.35 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, and an improvement from a loss of $0.50 per share a year ago, resulting in an earnings surprise of +14.63% [1] - The company posted revenues of $79.18 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.02%, but showing significant growth from year-ago revenues of $53.35 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - PROCEPT BioRobotics shares have declined approximately 40.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $83.74 million, and for the current fiscal year, it is -$1.49 on revenues of $325.61 million [7] Industry Outlook - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of stocks in this industry can be significantly influenced by the overall industry outlook, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Steris reported quarterly earnings of $2.34 per share, exceeding the Zacks Consensus Estimate of $2.32 per share, and up from $2.03 per share a year ago, representing an earnings surprise of +0.86% [1] - The company posted revenues of $1.39 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.36%, compared to $1.28 billion in the same quarter last year [2] - Over the last four quarters, Steris has surpassed consensus EPS estimates three times and topped consensus revenue estimates once [2] Future Outlook - The immediate price movement of Steris shares will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.39 on revenues of $1.41 billion, and for the current fiscal year, it is $10.12 on revenues of $5.83 billion [7] Industry Context - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Steris's stock performance [5][6]

Core Viewpoint - McKesson reported quarterly earnings of $8.26 per share, exceeding the Zacks Consensus Estimate of $8.23 per share, and showing an increase from $7.88 per share a year ago, indicating a positive earnings surprise of +0.36% [1][2] Financial Performance - The company achieved revenues of $97.83 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.82%, and up from $79.28 billion in the same quarter last year [2] - Over the last four quarters, McKesson has exceeded consensus EPS estimates three times and topped revenue estimates two times [2] Stock Performance - McKesson shares have increased approximately 24.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $8.61 for the coming quarter and $37.26 for the current fiscal year, alongside projected revenues of $103.81 billion and $406.16 billion respectively [7] - The Zacks Rank for McKesson is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which McKesson belongs, is currently in the top 25% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Viewpoint - Blackbaud (BLKB) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Blackbaud's Earnings Outlook - Blackbaud is projected to earn $4.40 per share for the fiscal year ending December 2025, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for Blackbaud has increased by 1.8%, reflecting a positive outlook for the company's earnings [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating [9][10]. - Blackbaud's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Group 1 - Novavax reported quarterly earnings of $0.62 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07 per share, representing an earnings surprise of +985.71% [1] - The company posted revenues of $239.24 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 102.74%, compared to year-ago revenues of $415.48 million [2] - Novavax has consistently surpassed consensus EPS estimates over the last four quarters [2] Group 2 - The stock has underperformed the market, losing about 16.3% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.22 for the coming quarter and $2.54 for the current fiscal year [4][7] - The Zacks Industry Rank indicates that the Medical - Biomedical and Genetics sector is currently in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8]

Company Performance - Holley Inc. reported quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share, and down from $0.10 per share a year ago, representing an earnings surprise of -10.00% [1] - The company posted revenues of $166.66 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.53%, but down from $169.5 million year-over-year [2] - Over the last four quarters, Holley has surpassed consensus EPS estimates just once and topped consensus revenue estimates three times [2] Stock Performance - Holley shares have lost approximately 32.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the coming quarter is $0.03 on revenues of $134.7 million, and for the current fiscal year, it is $0.20 on revenues of $591.48 million [7] Industry Outlook - The Automotive - Original Equipment industry, to which Holley belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

Company Performance - Telesat reported quarterly earnings of $1 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.69 per share, and showing improvement from a loss of $2.87 per share a year ago, resulting in an earnings surprise of +244.93% [1] - The company posted revenues of $76.69 million for the quarter ended June 2025, which missed the Zacks Consensus Estimate by 2.99% and decreased from year-ago revenues of $111.41 million [2] - Over the last four quarters, Telesat has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Telesat shares have increased approximately 47.1% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.11 on revenues of $65.31 million, and for the current fiscal year, it is -$2.29 on revenues of $298.96 million [7] - The estimate revisions trend for Telesat was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Satellite and Communication industry, to which Telesat belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which investors can track [5]